Similarly, empagliflozin activates the AMPK/mTOR pathway, upregulates LC3B expression, induces autophagy, and improves NAFLD in apolipoprotein E (ApoE) knockout mouse models (142). Here, MAP1LC3B is linked to metabolic dysfunction-associated steatotic liver disease.